Association of Duration of Sleep and Cardiovascular and Metabolic Comorbidities in Sleep Apnea Syndrome

Table 2

Polysomnography findings and features of OSAS of the patients in different cardiovascular and metabolic comorbidity groups.

	𝑁	No comorbidity	HT	DM	CHD
𝑁	312	150	122	44	38
Total sleep time, min		385.4±82.1	𝟑𝟒𝟔.𝟓±𝟖𝟖.𝟔 **	𝟑𝟑𝟓.𝟖±𝟖𝟕.𝟎 **	348.5±98.9
T90%, (%)		13.4±21.8	𝟐𝟐.𝟖±𝟑𝟎.𝟖 *	23.6±5.0	16.2±26.8
Sleep efficiency, (%)		87.5±10.5	𝟖𝟒.𝟓±𝟏𝟎.𝟓 *	84.0±13.3	84.8±11.4
WASO, (%)		2.2±6.3	𝟒.𝟑±𝟖.𝟒 *	4.0±9.1	3.5±7.6
REM, (%)		11.3±6.4	𝟗.𝟓±𝟕.𝟏 *	10.4±5.8	11.3±7.4
N3, (%)		21.8±12.4	21.0±14.6	𝟏𝟔.𝟒±𝟓.𝟖 *	20.0±15.0
AHI, (/hour)		30.3±27.9	33.1±30.7	31.3±31.5	22.4±22.2
Obstructive AHI		27.6±26.4	31.9±30.1	27.1±27.9	19.9±19.0
OSAS, %	173	58.5	60.2	48.7	48.4
Severe OSAS, %	120	38.5	38.0	34.1	27.8
CPAP prescribed, %	116	33.3	37.7	48.8	38.9
CPAP compliance, %	61	52.0	55.6	60.0	42.9

Means and ±SDs are given in the table, unless otherwise specified.
* 𝑃<0.05;
** 𝑃<0.01.
Significant findings are marked in bold type.
HT: hypertension, DM: diabetes mellitus, CHD: coronary heart disease, ESS: Epworth Sleepiness Scale, OSAS: obstructive sleep apnea syndrome, and WASO: wake after sleep onset.
OSAS: excessive daytime sleepiness and AHI≥5 or AHI≥15, regardless of excessive daytime sleepiness.
Severe OSAS was defined as AHI above 30/h.
CPAP compliance: reported usage of CPAP every night for more than 4 hours a night. CPAP compliance percentage was calculated in the patients who were prescribed CPAP therapy.